ABSI ABSCI CORP

Absci to Participate in Upcoming Investor Conferences

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

  • H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

    Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time
  • 24th Annual Needham Virtual Healthcare Conference

    Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time

Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: .

About Absci

is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our ™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit  and follow us on LinkedIn (), X (Twitter) (), and .

Investor Contact

Alex Khan

VP, Finance & Investor Relations

Media Contact



EN
26/03/2025

Underlying

ABSIABSCI CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ABSCI CORP

 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Announces Pricing of Public Offering of Common Stock

Absci Announces Pricing of Public Offering of Common Stock VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares o...

July 25, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Announces Proposed Public Offering of Common Stock

Absci Announces Proposed Public Offering of Common Stock VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten public offering of $50 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci. Ab...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Appoints Biopharma Leader Mary Szela to Board of Directors

Absci Appoints Biopharma Leader Mary Szela to Board of Directors Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal role...

July 7, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci to Participate in Upcoming Investor Conferences

Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will be participating in the following upcoming investor conferences. Jefferies Global Healthcare Conference (New York, NY)Presentation on Thursday, June 5 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time Goldman Sachs 46th Annual Global Healthcare Conference (Miami, FL)Presentation on Monday, June 9 at 8:...

May 20, 2025 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Reports Business Updates and First Quarter 2025 Financial and Op...

Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absc...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch